Bora Pharmaceuticals
Taipei, Taiwan
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Bora Pharmaceuticals
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Taipei, Taiwan
- Modalities
- Small Molecule (Oral Solid Dose), Biologics (Drug Substance & Drug Product), Monoclonal Antibody, Sterile Injectables / Aseptic Fill-Finish, Semi-Solids (creams, ointments, gels), Liquids (solutions, suspensions, ophthalmics, nasal sprays), Lyophilization
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Bora Pharmaceuticals
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSmall Molecule (Oral Solid Dose), Biologics (Drug Substance & Drug Product), Monoclonal Antibody, Sterile Injectables / Aseptic Fill-Finish, Semi-Solids (creams, ointments, gels), Liquids (solutions, suspensions, ophthalmics, nasal sprays), Lyophilization
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (7 modalities)
Recent News 10 articles
Bora Group to acquire MacroGenics manufacturing for $122.5 million - Vietnam Investment Review - VIR
MacroGenics Sells Maryland Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million - citybiz
Bora Pharmaceuticals Posts Steady 2025 Growth; CDMO Revenue (incl. inter-company) Surges 53.8% - 全球醫療採購網
Bora Pharmaceuticals to Acquire MacroGenics Manufacturing Facility in $122.5 Million Deal - biobuzz.io
Bora snaps up MacroGenics’ manufacturing, CDMO operations for up to $127.5M - Fierce Pharma
CDMO Bora locks in 5-year, $250M production agreement with GSK - Fierce Pharma
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract - Business Wire
Bora Pharmaceuticals, GSK Renew Global Manufacturing Contract for $250M - Contract Pharma
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals - GlobeNewswire
Bora Pharmaceuticals marks five years in Mississauga with expanded CDMO capabilities and continued global growth - Manufacturing Chemist
Frequently Asked Questions About Bora Pharmaceuticals
What is Bora Pharmaceuticals's CDMO Signal Score?
Bora Pharmaceuticals has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Bora Pharmaceuticals for a manufacturing program?
Use the free AI matchmaker to compare Bora Pharmaceuticals against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Pyramid Pharma Services (Pyramid Laboratories, Inc.)
Costa Mesa, CA
Biologics, Sterile Injectables / Aseptic Fill-Finish, Lyophilization, Peptides, Small Molecules, siRNA/Oligonucleotide Injectable, Formulation Development, Analytical & Stability Testing
TaiMed Biologics
Zhubei City, Hsinchu County, Taiwan
Monoclonal Antibody, Biologics Drug Substance, Biologics Drug Product
EirGenix
Zhubei City, Hsinchu County, Taiwan
Monoclonal Antibody, Bispecific/Polyclonal Antibody, Recombinant Protein, ADC, Biosimilars, Plasmid DNA
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 83.5
Monoclonal Antibody, Recombinant Protein, AAV, Plasmid DNA
Rentschler Biopharma
Laupheim, Germany
Signal Score: 79.9
Monoclonal Antibody, Recombinant Protein